Plinabulin Dramatically Boosts ADC Efficacy, Survival in Preclinical Cancer Study
summarizeSummary
BeyondSpring Inc. announced compelling new preclinical data at the AACR 2026 meeting, demonstrating that its lead asset, Plinabulin, significantly enhances both the anticancer efficacy and safety of antibody-drug conjugate (ADC) therapies. The data showed Plinabulin dramatically improved complete response rates and survival when combined with leading ADCs like T-DXd and Dato-DXd, while also improving tolerability by reducing animal death and potentially mitigating neutropenia. This development is highly material for BeyondSpring, as it significantly broadens the potential market and strategic value of Plinabulin beyond its existing Phase 3 NSCLC program, positioning it as a potential backbone agent for a major class of oncology drugs. Investors will be watching for the initiation of future ADC combination studies, which the company indicated as a natural next chapter in Plinabulin's clinical development.
At the time of this announcement, BYSI was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71.5M. The 52-week trading range was $1.21 to $3.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.